Philips Sonicare

Statins and Diabetes: Real Concern or Much Ado About Nothing?

From Forbes

In New York Times Op-Ed piece on Monday, Eric Topol comments on last week’s announcement by the FDA that it was changing the label for statins. Topol focuses on the new warning that statins raise the risk of diabetes. He opens with a provocative statement: We’re overdosing on cholesterol-lowering statins, and the consequence could be a sharp increase in the incidence of Type 2 diabetes. Topol does the math and calculates that 20 million Americans taking statins equates to 100,000 new statin-induced diabetics: Not a good thing for the public health and certainly not good for the individual affected with a new serious chronic illness… If there were a major suppression of heart attacks or strokes or deaths, that might be justified. But in patients who have never had heart disease and are taking statins to lower their risk (so-called primary prevention), the reduction of heart attacks and other major events is only 2 per 100. And we don’t know who the 2 per 100 patients are who benefit or the one per 200 who will get diabetes! Moreover, the margin of benefit to risk is quite narrow.

Read article

About author
Dr. Ken Serota, DDS, MMSc Author of over 70 publications, Ken has lectured on Endodontics and Implantology around the world. MMSc from the Harvard-Forsyth Dental Center in Boston, MA; Fellow of the Pierre Fauchard Academy. Ken is the founder of ROOTS – an online educational forum for dentists from around the world who wish to learn cutting edge endodontic therapy.
Submit your comment

Please enter your name

Your name is required

Please enter a valid email address

An email address is required

Please enter your message

*

Blog OHJ © 2014 All Rights Reserved

Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: